Monday, March 16, 2026

Why Demon Slayer Missed Out on the Golden Globe Despite Record-Breaking Success

Japanese media expressed disappointment that "Demon Slayer" missed a Golden Globe despite its box office success. "K-Pop Demon Hunters" won instead.

From ‘Trauma Center’ to ‘Princess Hours’: Ju Ji Hoon Reflects on 20 Years in the Industry

Ju Ji Hoon returns to "You Quiz on the Block," sharing insights from his career and featuring rising star Kim Chae Yeon.

North Korean Military Violated MDL 10 Times In November Alone, Concentrated In Goseong Gangwon

North Korean forces have violated the Military Demarcation Line multiple times, prompting South Korean military responses without protocol changes.

Tag: drugs

North KoreaKoreaKimMilitarySouth KoreaAIrelationsmarketInternational

Dongkoo Bio&Pharma Invests 1 Billion KRW in GenomAndCompany: What This Means for ADC Drug Development

Dongkoo Bio&Pharma invests 1 billion KRW in Genome & Company to enhance antibody and ADC drug development strategies.

Will Novo Nordisk’s 50% Price Cut on Wegovy Spark a Price War in Korea’s Obesity Drug Market?

Novo Nordisk's price cuts for GLP-1 obesity treatments in the U.S. may influence South Korean market dynamics, though immediate effects seem limited.

Unlocking Weight Loss: How Celltrion’s New CT-G32 and Oral Multi-Action Drug Will Change the Game

Celltrion aims to lead the obesity treatment market with innovative drugs, enhancing efficacy and patient convenience through dual approaches.

K-Bio Revolution: How Korean Biopharmaceuticals Are Conquering the Global Market in 2026

South Korea's pharmaceutical industry thrives with innovative drugs like botulinum toxins and cancer treatments, targeting global markets.

As Wegovy and Mounjaro Soar, Korean Biotechs Seek a Slice of the Obesity Drug Market

South Korean firms are innovating in the GLP-1 obesity treatment market, developing unique drugs to compete with industry leaders.

Big Pharma Braces for $300 Billion Loss as Blockbuster Drug Patents Expire

Global pharma faces $300B losses from patent expirations, prompting a shift to multi-indication drugs and innovative therapies.

ProGen’s PG-110 Targets Fat Loss Without Muscle Waste—Next-Gen Obesity Drug in Focus

ProGen will present non-clinical results of its obesity drug PG-110 at the ADA conference, targeting muscle preservation and weight loss.

High on Gummies: The New Disturbing Marijuana Trend

The police arrested several people after ingesting gummies with cannabis components and reporting symptoms of dizziness to 119, the Korean Emergency Service. On the 12th,...

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.